Hussman Strategic Advisors Inc. bought a new stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm bought 315,000 shares of the biotechnology company's stock, valued at approximately $2,362,000. Hussman Strategic Advisors Inc. owned about 0.15% of BioCryst Pharmaceuticals as of its most recent filing with the SEC.
A number of other hedge funds and other institutional investors have also bought and sold shares of the company. CWM LLC increased its holdings in shares of BioCryst Pharmaceuticals by 167.5% during the 1st quarter. CWM LLC now owns 53,750 shares of the biotechnology company's stock worth $403,000 after acquiring an additional 33,656 shares during the last quarter. Cerity Partners LLC boosted its stake in BioCryst Pharmaceuticals by 203.6% in the 1st quarter. Cerity Partners LLC now owns 36,410 shares of the biotechnology company's stock valued at $273,000 after purchasing an additional 24,418 shares during the period. Allspring Global Investments Holdings LLC bought a new stake in BioCryst Pharmaceuticals in the 1st quarter valued at $79,000. Wealth Enhancement Advisory Services LLC lifted its position in shares of BioCryst Pharmaceuticals by 113.7% during the 1st quarter. Wealth Enhancement Advisory Services LLC now owns 37,671 shares of the biotechnology company's stock valued at $283,000 after acquiring an additional 20,043 shares during the period. Finally, SG Americas Securities LLC lifted its position in shares of BioCryst Pharmaceuticals by 5.2% during the 1st quarter. SG Americas Securities LLC now owns 43,496 shares of the biotechnology company's stock valued at $326,000 after acquiring an additional 2,146 shares during the period. Institutional investors and hedge funds own 85.88% of the company's stock.
BioCryst Pharmaceuticals Stock Performance
BioCryst Pharmaceuticals stock traded down $0.09 during midday trading on Friday, hitting $8.61. 3,104,683 shares of the company's stock were exchanged, compared to its average volume of 3,039,523. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.02 and a 52-week high of $11.31. The stock has a 50-day moving average price of $9.92 and a two-hundred day moving average price of $8.69. The company has a market cap of $1.80 billion, a P/E ratio of -33.12, a PEG ratio of 1.41 and a beta of 1.04.
Analyst Upgrades and Downgrades
A number of equities analysts have issued reports on the company. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a report on Monday, June 30th. Wall Street Zen cut BioCryst Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research note on Saturday, June 28th. Barclays increased their price target on BioCryst Pharmaceuticals from $8.00 to $11.00 and gave the company an "equal weight" rating in a research note on Wednesday, May 7th. HC Wainwright reissued a "buy" rating and issued a $30.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, May 6th. Finally, Wedbush increased their price target on BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research note on Monday, June 30th. One investment analyst has rated the stock with a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $16.70.
Check Out Our Latest Research Report on BioCryst Pharmaceuticals
BioCryst Pharmaceuticals Profile
(
Free Report)
BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.
Featured Stories
Before you consider BioCryst Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioCryst Pharmaceuticals wasn't on the list.
While BioCryst Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
